期刊
ALIMENTARY PHARMACOLOGY & THERAPEUTICS
卷 43, 期 4, 页码 482-513出版社
WILEY
DOI: 10.1111/apt.13491
关键词
-
资金
- Shire
- Ferring
- Janssen
- AbbVie
- GESA Bushell Postdoctoral Fellowship
- David Bickart Clinician Research Fellowship from the University of Melbourne
BackgroundAcute severe ulcerative colitis (ASUC) is a life-threatening condition for which optimal management strategies remain ill-defined. AimTo review the evidence regarding the natural history, diagnosis, monitoring and treatment of ASUC to inform an evidence-based approach to management. MethodsRelevant articles addressing the management of ASUC were identified from a search of MEDLINE, the Cochrane Library and conference proceedings. ResultsOf ASUC, 31-35% is steroid-refractory. Infliximab and ciclosporin salvage therapies have improved patient outcomes in randomised controlled trials. Short-term response rates (within 3 months) have ranged from 40% - 54% for ciclosporin and 46-83% for infliximab. Long-term clinical response rates (1 year) have ranged from 42%-50% for ciclosporin and 50-65% for infliximab. Short-term and long-term colectomy rates have been respectively: 26-47% and 36-58% for ciclosporin, and 0-50% and 35-50% for infliximab. Mortality rates for ciclosporin and infliximab-treated patients have been: 0-5% and 0-2%, respectively. At present, management challenges include the selection, timing and assessment of response to salvage therapy, utilisation of therapeutic drug monitoring and long-term maintenance of remission. ConclusionsOptimal management of acute severe ulcerative colitis should be guided by risk stratification using predictive indices of corticosteroid response. Timely commencement and assessment of response to salvage therapy is critical to reducing morbidity and mortality. Emerging pharmacokinetic models and therapeutic drug monitoring may assist clinical decision-making and facilitate a shift towards individualised acute severe ulcerative colitis therapies.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据